US Advises Seniors Against Getting Chikungunya Vaccine Due to Safety Concerns
US health officials advise travelers aged 60 and above to avoid the chikungunya vaccine amid ongoing safety investigations due to potential side effects in older adults.
In recent health developments, US health authorities have issued a cautionary message to travelers aged 60 and above, recommending against receiving the chikungunya vaccine while investigations into potential side effects are ongoing. The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) released notices last week concerning the vaccine, Valneva's Ixchiq, which was previously recommended for adults traveling to regions affected by chikungunya.
Chikungunya is a mosquito-borne illness endemic to tropical areas, characterized by high fever, severe joint pain, and fatigue. Despite its typically mild initial symptoms, the disease can cause prolonged joint issues and significant health problems. Annually, around 100 to 200 cases are reported in the United States among travelers returning from affected regions.
The vaccine, developed using a weakened form of the chikungunya virus, was introduced last year as a preventive measure for at-risk populations. However, recent reports have raised safety concerns, particularly regarding older adults. A review by vaccine experts revealed six cases of individuals aged 65 and above who experienced heart or brain-related symptoms shortly after vaccination. Notably, most of these individuals had preexisting health conditions. Additional similar cases have been documented internationally.
Regulatory agencies in Europe are also examining these cases as part of their review process. In response to the emerging data, US advisory panels have recommended placing a precaution on the vaccine’s use in seniors over 65. Meanwhile, another chikungunya vaccine by Bavarian Nordic, Vimkunya, remains recommended for travelers aged 12 and older, though decisions on its widespread use are yet to be finalized.
This development underscores the importance of carefully evaluating vaccine safety, especially in vulnerable populations. Travelers are advised to consult healthcare providers for personalized recommendations and remain informed about ongoing safety assessments regarding chikungunya vaccination.
Source: https://medicalxpress.com/news/2025-05-health-older-chikungunya-vaccine.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Link Between Gastroesophageal Reflux Disease and Increased Risk of Pulmonary Disorders
Gastroesophageal reflux disease (GERD) is linked to a higher risk of developing various lung diseases. New research suggests that managing GERD effectively may reduce this risk and improve respiratory health.
Understanding Desiccant Sachets: What They Are and How They Work
Discover what silica gel and other desiccant sachets are, how they work to protect products from moisture, and their safety considerations for everyday use.
Challenges Faced by Nurses in Providing End-of-Life Care in Aged Care Homes
Recent research highlights the barriers nurses face in delivering quality end-of-life care in Australian aged care homes, emphasizing the need for systemic reform and targeted support to improve resident outcomes.
GERD and Its Potential Link to Ear Disorders Including Tinnitus and Meniere Disease
Emerging evidence links Gastroesophageal Reflux Disease (GERD) to increased risks of ear disorders such as tinnitus, Meniere disease, and hearing loss. New research highlights the potential causal relationship and its implications for ear health management.